Rimacept Tablet 5 mg (Donepezil Hydrochloride Monohydrate)

Adult dose

○ Adults: Administer donepezil hydrochloride 5 mg once daily at bedtime. If sleep disturbances such as abnormal dreams, nightmares, or insomnia occur, morning administration of this medicine may be considered. Since donepezil concentrations reach steady state 15 days after administration and the frequency of adverse reactions may be affected by the rate of dose escalation, administer the 5 mg dose for 4~6 weeks. After evaluating the clinical response during this period, the dose may be increased to 10 mg. When increasing the dose to 10 mg daily, monitor for gastrointestinal adverse reactions. If treatment with this medicine is discontinued, its effects gradually diminish, and no rebound effect occurs following abrupt discontinuation. ○ Women aged 85 years or older with low body weight: Because adverse reactions occur more frequently, careful monitoring is required. Older women with low body weight should not exceed 5 mg daily.

Child dose

○ Children: There is no experience with use in children.

This medication contains donepezil hydrochloride and is mainly used for the treatment of symptoms of Alzheimer's type dementia. Firstly, this drug should not be used in certain patients. For example, those who are allergic to this medication or its components, pregnant women or women who may become pregnant, and nursing mothers should not take this medication. Patients with genetic disorders affecting lactose breakdown should also avoid this medication. Additionally, patients with heart disease, a history of peptic ulcers, asthma, chronic obstructive pulmonary disease, and extrapyramidal disorders such as Parkinson's disease should be administered this medication cautiously. This medication may affect heart rhythm, put a strain on the stomach, and potentially worsen respiratory symptoms. Various adverse reactions may occur when taking this medication. Heart-related issues (e.g. bradycardia, heart block, etc.), gastrointestinal bleeding, liver function abnormalities, seizures, movement disorders, shortness of breath, acute pancreatitis, acute renal failure have been reported. Commonly, nausea, vomiting, diarrhea, headaches, dizziness, insomnia, skin rash may also be present. While taking this medication for dementia, regular assessment of treatment efficacy should be conducted, and discontinuation should be considered if it is deemed ineffective. This medication may also affect driving or operating machinery, so caution is necessary. This medication may interact with other drugs, particularly those metabolized by the liver or those affecting the heart. Co-administration with certain antibiotics, antidepressants, antiarrhythmic agents can impact heart rhythm, so it is important to follow the physician's instructions. Pregnant or nursing women should avoid using this medication unless absolutely necessary and after consulting a healthcare professional. Safety in pediatric patients has not yet been established, so this medication is not used in children. In case of overdose, severe symptoms such as nausea, vomiting, bradycardia, respiratory depression may occur, and immediate contact with a medical institution is necessary. Atropine may be used as an antidote. Finally, this medication should be stored out of the reach of children and should not be transferred to other containers.

• Syncope
• bradycardia
• heart block
• prolonged QT interval
• myocardial infarction
• heart failure
• peptic ulcer
• perforated duodenal perforation
• gastrointestinal bleeding
• hepatitis

This medication should be stored in a tightly closed container to prevent air or moisture from entering. The storage temperature should be kept at room temperature between 1 degree and 30 degrees Celsius.

Appearance

White round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle